Onesource Specialty Pharma Limited (ONESOURCE) Q2 FY27 Financial Results: PAT ₹637 Cr & Revenue ₹4,490 Cr

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
MetricValue
Revenue₹4,490 Cr
Net Profit (PAT)₹637 Cr
📢 Key Event
OneSource Specialty Pharma announced Q1FY27 results with 37% YoY revenue growth and 39% YoY EBITDA growth.
🔄 What Changed
Revenue grew 37% YoY to ₹4,490m; EBITDA grew 39% YoY to ₹1,233m with margin expanding 600bps to 27.5%; Adjusted PAT rose 72% YoY to ₹637m.
🔮 What's Next
FY28 organic revenue guidance of $400 million and 40% EBITDA margin reaffirmed.
💡 Investor Takeaway
Strong top-line and margin expansion driven by semaglutide and capacity gains signal accelerating growth momentum.

OneSource Specialty Pharma reported Q1FY27 revenue of ₹4,490m, up 37% YoY and 5% QoQ, driven by semaglutide commercialization and new MSA contracts. EBITDA rose 39% YoY to ₹1,233m with margin expanding 600bps to 27.5%, reflecting operating leverage. Adjusted PAT increased 72% YoY to ₹637m, with adjusted EPS at [amount not verified]FY28 guidance reaffirmed $400m organic revenue and 40% EBITDA margin. The company highlighted capacity expansion, including a second cartridge line commercializing in Q2, and strengthened biosimilics and GLP-1 franchise momentum.

📄 View Original Announcement (PDF)

About Onesource Specialty Pharma Limited (ONESOURCE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹17,366.55 Cr ROE: -0.8% ROCE: 0.9%

View full ONESOURCE stock details →

📡 Get AI alerts when ONESOURCE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ONESOURCE — Free

📊 More ONESOURCE filings

See all ONESOURCE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ONESOURCE files new disclosures

Track ONESOURCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ONESOURCE — Free

Free account · 2 AI queries/day